tbuckley/cabot-search huggingface dataset:
Bendamustine and cetuximab as an alternative therapeutic option for recurrent head and neck squamous cell carcinoma.
Authors: B. Tschechne, I. Wildfang, H. Niebuhr, J. Borghardt, H. Zakaria, S. Fanaei, S. Luft, W. Jordan
Journal: Journal of Clinical Oncology (2010)

e16029 Background: The risk of recurrence in patients with squamous cell cancer of the head and neck (SCCHN) is high. In general, the therapeutic options after failure of a standard cisplatin-based chemotherapy ± radiotherapy are extremely limited due to the prior intensity of therapy and/or the reduced physical condition of the patient. As a monotherapeutic drug even in relapsed SCCHN cetuximab has shown activity. Also there are reports of the activity of bendamustin in relapsed SCCHN. Because of the moderate toxicity profile of bendamustine, we used it as a combination partner to cetuximab. In this highly palliative situation after failure of standard therapy in inoperable patients we treated 28 patients with the combination of cetuximab and bendamustine. Methods: We administered cetuximab in a starting dose (day 0) of 400 mg/m2, from day 8 subsequently weekly 250 mg/m2 till a progressive disease had to be observed. Bendamustine (Day 9, 10) 100 mg/m2 in a three week cycle also till progression. Results: So far, this therapy seems to be highly effective, so after 26 weeks 10 patients showed a partial response, 10 patients a stable disease and 8 patient was progressive. The therapy has been well tolerated (grade I/II rash symptoms by cetuximab), hematological grade III/IV toxicities were not observed. Conclusions: Similar therapeutic results have not been observed by us before and thus should be investigated further. No significant financial relationships to disclose.
Low‐grade endotoxemia and platelet activation in cirrhosis
Authors: Valeria Raparelli, Stefania Basili, Roberto Carnevale, Laura Napoleone, Maria Del Ben, Cristina Nocella, Simona Bartimoccia, Cristina Lucidi, Giovanni Talerico, Oliviero Riggio, Francesco Violi
Journal: Hepatology (2016)

Patients with cirrhosis may display impaired or enhanced platelet activation, but the reasons for these equivocal findings are unclear. We investigated if bacterial lipopolysaccharide (LPS) is implicated in platelet activation. In a cross‐sectional study, conducted in an ambulatory care clinic and hospital, comparing 69 cirrhosis patients and 30 controls matched for sex, age, and atherosclerotic risk factors, serum levels of LPS, soluble cluster of differentiation 40 ligand and p‐selectin (two markers of platelet activation), and zonulin (a marker of gut permeability) were investigated. Ex vivo and in vitro studies were also performed to explore the effect of LPS on platelet activation. Compared to controls, cirrhosis patients displayed higher serum levels of LPS (6.0 [4.0‐17.5] versus 57.4 [43.4‐87.2] pg/mL, P &lt; 0.0001), soluble cluster of differentiation 40 ligand (7.0 ± 2.2 versus 24.4 ± 13.3 ng/mL, P &lt; 0.0001), soluble p‐selectin (14.2 ± 4.05 versus 33.2 ± 15.2 ng/mL, P &lt; 0.0001), and zonulin (1.87 ± 0.84 versus 2.54 ± 0.94 ng/mL, P &lt; 0.006). LPS significantly correlated with zonulin ( r = 0.45, P &lt; 0.001). Ex vivo studies showed that platelets from cirrhosis patients were more responsive to the agonists independently from platelet count; this phenomenon was blunted by incubation with an inhibitor of Toll‐like receptor 4. In vitro study by normal platelets showed that LPS alone (50‐150 pg/mL) did not stimulate platelets but amplified platelet response to the agonists; Toll‐like receptor 4 inhibitor blunted this effect. Conclusion: LPS may be responsible for platelet activation and potentially contributes to thrombotic complications occurring in cirrhosis. (H epatology 2017;65:571‐581).
Transient Expansion of Stem-Like Tumor-Initiating Cells Contributes to Chemoresistance during Anti-Angiogenic Therapies in Hepatocellular Carcinomas
Authors: D. Castven, C. Czauderna, D. Becker, M.A. Wörns, S.S. Thorgeirsson, H. Lang, P.R. Galle, J.U. Marquardt
Journal: Journal of Hepatology (2016)
Hepatotoxicity Associated with Non-Steroidal Anti-Inflammatory Drugs. A Comparative Analysis among Ibuprofen, Diclofenac and Nimesulide fromthe Spanish and Latin-American Dili Registries
Authors: A. Gonzalez-Jimenez, I. Medina-Cáliz, M. Robles-Díaz, M.E. Zoubek, P. Díaz-Jimenez, M.R. Cabello, A. Ortega-Alonso, M. García-Cortes, B. García-Muñoz, M.C. Fernandez, M. Slim, M. Romero-Gómez, F. Bessone, N. Hernandez, M. Arrese, E. Montane, H. Hallal, J.A. Sanabria-Cabrera, R. Sanjuan-Jimenez, M.I. Lucena, R.J. Andrade
Journal: Journal of Hepatology (2016)
Heterogeneity of CD34 and CD38 expression in acute B lymphoblastic leukemia cells is reversible and not hierarchically organized
Authors: Zhiwu Jiang, Manman Deng, Xinru Wei, Wei Ye, Yiren Xiao, Simiao Lin, Suna Wang, Baiheng Li, Xin Liu, Gong Zhang, Peilong Lai, Jianyu Weng, Donghai Wu, Haijia Chen, Wei Wei, Yuguo Ma, Yangqiu Li, Pentao Liu, Xin Du, Duanqing Pei, Yao Yao, Bing Xu, Peng Li
Journal: Journal of Hematology & Oncology (2016)

The existence and identification of leukemia-initiating cells in adult acute B lymphoblastic leukemia (B-ALL) remain controversial. We examined whether adult B-ALL is hierarchically organized into phenotypically distinct subpopulations of leukemogenic and non-leukemogenic cells or whether most B-ALL cells retain leukemogenic capacity, irrespective of their immunophenotype profiles. Our results suggest that adult B-ALL follows the stochastic stem cell model and that the expression of CD34 and CD38 in B-ALL is reversibly and not hierarchically organized.
The importance of patient involvement in implementing electronic health record systems
Authors: Windu Kusumo
Journal: BMJ (2016)

Health providers have paid much attention to the meaningful use of electronic health records (EHRs), but less concern has been devoted to reviewing patient safety.1 In their study,2 Barnett and colleagues found no general correlation between EHR implementation and short term inpatient mortality, adverse events, or readmissions in 17 hospitals in the US.2

However, the …
A time-in-motion study of oral ibandronate versus iv zoledronic acid for treatment of metastatic bone disease in breast cancer patients
Authors: A. Wardley, J.-J. Body, M. Neary
Journal: Journal of Clinical Oncology (2005)

6123 Background: Oral bisphosphonates avoid time for administration and monitoring and use of infusion supplies associated with iv bisphosphonates. We used time-in-motion methods in a pharmacoeconomic sub-study to a clinical trial of oral ibandronate vs iv zoledronic acid to estimate medical resource use differences. Methods: At the Week 8 study visit, detailed assessments of resource use were made in patients receiving oral ibandronate 50mg/day (n=19) or iv zoledronic acid 4mg every 3–4 weeks (n=17) at six outpatient clinics in Belgium, Switzerland, Russia and the UK. Staff time associated with bisphosphonate administration, laboratory tests, infusion supplies and medications were recorded. Results: Most patients (94% of ibandronate and 88% of zoledronic acid patients) were not receiving iv chemotherapy concurrently. In Western European sites, average clinic time associated with zoledronic acid administration was 1 hr 25 min longer per patient than with ibandronate (Table). Additional infusion supplies were required for zoledronic acid in patients not receiving iv chemotherapy. Medication use and laboratory tests were similar between groups. In the Russian site, mean duration of the Week 8 visit was 2 hr 25 min longer with zoledronic acid, and included a longer mean preparation time before infusion of 229 min. Mean clinician time was also greater with zoledronic acid (47 versus 32 min with ibandronate) and mean nurse time was greater (19 versus 3 min). Some patients were required to stay overnight for infusions, due to transportation needs. Conclusions: Compared with iv zoledronic acid, oral ibandronate provides medical care utilization savings in staff time and infusional supplies. This further assists clinics having high case loads by freeing staff to manage additional patients. The potential benefits will be greatest when patients are receiving oral anticancer therapies or have completed iv chemotherapy. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Roche Roche
Multimethod Clinical Assessment of Patterns and Prevalence of Nonadherence (NA) to Imatinib Treatment (IMRx) in Patients (Pts) with Chronic Myeloid Leukemia (CML): Results from the ADAGIO Study.
Authors: Marie-Anne van Lierde, Filipo Serra, Larissa De Rop, Eric Strobbe, Karen MacDonald, Stefaan Vancayzeele, Sabina De Geest, Laurie Letvak, Tara Albrecht, Ivo Abraham
Journal: Blood (2007)
Treatment Irrespective of Symptoms Is a Major Predictive Factor for Thrombus Resolution in Patients with Portal Vein Thrombosis
Authors: Yuan-Bin Yu, Chien-Wen Yang, Chun-Yu Liu, Jyh-Pyng Gau, Ying-Chung Hong, Liang-Tsai Hsiao, Jin-Hwang Liu, Tzeon-Jye Chiou, Hui-Chi Hsu, Cheng-Hwai Tzeng
Journal: Blood (2012)
Incentive and Restriction in Combination—Make Food Assistance Healthier With Carrots and Sticks
Authors: Marlene B. Schwartz
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
UGT2B28 Genomic Variation is Associated with Hepatitis B E-Antigen Seroconversion in Response to Entecavir or Peginterferon Therapy
Authors: C.-T. Yeh, C.-L. Lin, R.-N. Chien, K.-H. Liang, C.-W. Hsu, M.-W. Lai
Journal: Journal of Hepatology (2016)
A Phase 1 Dose-Escalation Study of the Novel KSP Inhibitor ARRY-520 in Advanced Leukemias.
Authors: Guillermo Garcia-Manero, H. Jean Khoury, Gautam Borthakur, Farhad Ravandi, Tapan Kadia, Zeev Estrov, Elias Jabbour, Maria Cielo Foudray, Martha Arellano, Amelia Langston, Beverly Bethelmie-Bryan, Selena Rush, Burgess Freeman, Heidi Simmons, Mieke Ptaszynski, Hagop Kantarjian
Journal: Blood (2009)
Safety and Efficacy of New Daa Regimens in Kidney and Liver Transplant Recipients with Hepatitis C: Interval Results from the HCV-Target Study
Authors: K.R. Reddy, M.S. Sulkowski, M. Hassan, J. Levitsky, J. O’Leary, R.S. Brown, E.C. Verna, A. Kuo, R.T. Stravitz, J.K. Lim, V. Saxena, D.R. Nelson, P. Hayashi, M. Vainorius, M.W. Fried, N. Terrault
Journal: Journal of Hepatology (2016)
Most mild chronic kidney disease is benign, GP study finds
Authors: Jacqui Wise
Journal: BMJ (2016)

The vast majority of patients with mild chronic kidney disease have a benign condition and are at low risk of progression and complications, a primary care study published in PLOS Medicine has found.

The study said that GPs should focus on identifying the minority of people who are at high risk of adverse outcomes for more intensive treatment and referral to a kidney specialist.1 Those at low risk can be reassured and spared unnecessary treatment or referral.

Most studies on …
The Xenograft of Adipose Derived-Human Mesenchymal Stem Cells Attenuates Hepatic Damage in Rats with Chronic Liver Injury
Authors: N. Enciso, J. Amiel, J. Pando, N. Rojas, C. Cisneros, E. Nava, F. Fabian, J. Enciso
Journal: Journal of Hepatology (2016)
Galectin-3 Deficiency Exacerbates Liver Steatosis but Protects from Steatohepatitis and IL-33/IL-13 Dependent Fibrosis in HFD-Induced Obesity Mouse Model
Authors: I. Jeftic, N. Jovicic, J. Pantic, N. Arsenijevic, M.L. Lukic, N. Pejnovic
Journal: Journal of Hepatology (2016)
A Territory-Wide Study on the Seroprevalence of Hepatitis B Virus in the General Population after Universal Hepatitis B Immunization ERA in Hong Kong, China
Authors: S.H.K. Liu, W.-K. Seto, D.K.-H. Wong, J.C.-H. Yuen, Y.F.F. Lam, K.S.M. Cheung, W.P.E. To, K.L.M. Ko, L.Y.L. Mak, C.-L. Lai, M.-F. Yuen
Journal: Journal of Hepatology (2016)
Home-Based Management of Refractory Ascites by Permanent Tunneled Peritoneal Catheter is an Effective Replacement for Recurrent Large Volume Paracentesis
Authors: C.H.Z. Siederdissen, P. Solbach, R. Taubert, S. Ziegert, K. Port, A. Schneider, K. Hueper, M. Manns, H. Wedemeyer, E. Jäckel
Journal: Journal of Hepatology (2016)
HIV Coinfection Impairs Response to DAA-Based HCV Therapy
Authors: K. Neukam, M. Suárez-Santamaría, A. Rivero-Juárez, A. Romero-Palacios, E. Ortega, I. de los Santos-Gil, J. Cucurull, F. Vera-Méndez, J.A. Pineda
Journal: Journal of Hepatology (2016)
Harnessing Gene Expression Profiles for the Identification of Drug Resistance Genes in Pediatric AML
Authors: Costa Bachas, Gerrit Jan Schuurhuis, C. Michel Zwaan, Marry M. van den Heuvel-Eibrink, Monique L. Den Boer, Zinia J. Kwidama, Evelina S. De Bont, Dirk Reinhardt, Ursula Creutzig, Valérie de Haas, Yehuda Assaraf, Gertjan J.L. Kaspers, Jacqueline Cloos
Journal: Blood (2012)
IL-1 Inhibition and Vascular Function in CKD
Authors: Kristen L. Nowak, Michel Chonchol, Talat Alp Ikizler, Heather Farmer-Bailey, Natjalie Salas, Rafia Chaudhry, Wei Wang, Gerard Smits, Isak Tengesdal, Charles A. Dinarello, Adriana M. Hung
Journal: Journal of the American Society of Nephrology (2016)

Vascular endothelial dysfunction and increased arterial stiffness contribute to increased cardiovascular risk in patients with CKD who exhibit chronic systemic inflammation. Because chronic inflammation contributes to vascular dysfunction, blocking inflammation may reduce cardiovascular risk in patients with CKD. In a two-site, double-blind trial, we randomized 42 adult patients with stage 3-4 CKD who were already receiving optimal background therapy to receive either IL-1 trap rilonacept or placebo for 12 weeks. Coprimary end points included change in brachial artery flow-mediated dilation (FMDBA) and aortic pulse-wave velocity (aPWV) after 4, 8, and 12 weeks. Exploratory end points included change in high-sensitivity C-reactive protein (hsCRP), FMDBA after acute ascorbic acid infusion, and vascular endothelial cell protein expression of NADPH oxidase. Participants were 63±11 (mean±SD) years of age and 24% were women; mean eGFR was 38±13 ml/min per 1.73 m2 Compared with placebo, rilonacept improved FMDBA (baseline: 3.36%±2.06% [mean±SD], 12 weeks: 2.45%±2.29% with placebo and baseline: 3.75%±3.12%, 12 weeks: 4.86%±3.20% with rilonacept; P<0.01), without changing aPWV (P=0.56). Rilonacept also reduced hsCRP levels (median [interquartile range]) (baseline: 4.60 [1.90-8.22] mg/L, 12 weeks: 2.16 [0.92-7.38] mg/L; P<0.01) and endothelial cell NADPH oxidase expression (P<0.05). Acute infusion of ascorbic acid to inhibit superoxide production associated with a nonsignificant trend toward increased FMDBA in the placebo group (P=0.07) but not the rilonacept group (P=0.56). Rilonacept was well tolerated (five adverse events versus two with placebo). In conclusion, treatment with an IL-1 trap improved FMDBA without changing aPWV and reduced systemic inflammation in patients with CKD.
Chronic Lymphocytic Leukemia: Proliferative and Apoptotic Profile on Lymph Node, Studied by Immunohistochemistry Including the Proliferation Centers
Authors: Sotirios P. Sachanas, Georgia Levidou, Maria K. Angelopoulou, Maria Moschogiannis, Xanthi Yiakoumis, Theodoros P. Vassilakopoulos, Flora Kontopidou, Christina H. Kalpadakis, Pantelis Tsirkinidis, Aglaia Dimitrakopoulou, Styliani Kokoris, Panayiotis Panayiotidis, Helen A. Papadaki, Eustratios Patsouris, Penelope Korkolopoulou, Gerassimos Pangalis
Journal: Blood (2011)
Nitric Oxide Sensitizes B-NHL Cells to TRAIL-Mediated Apoptosis through Induction of RKIP, Inhibition of YY1 and Upregulation of DR5.
Authors: Stavroula Baritaki, Alina Katsman, Sara Huerta-Yepez, Kam C. Yeung, James Berenson, Benjamin Bonavida
Journal: Blood (2006)
A new agent, liposomal cisplatin, in the treatment of relapsed or metastatic childhood solid tumors: Toxicity and clinical effectiveness.
Authors: Nurdan Tacyildiz, Gulsan Yavuz, Emel Cabi Unal, Handan Dincaslan, Fikret Asarcikli, Gulsah Tanyildiz
Journal: Journal of Clinical Oncology (2016)

e22006 Background: Cisplatin is effective treatment for several solid tumors with side effects like nefrotoxicity or ototoxicity. Liposomal cisplatin (Lipoplatin, L-platin) is a new cisplatin formulation and investigated in a small number of adult cancer studies to compare with cisplatin. There is no childhood studies. Our aim is to investigate renal toxicity, myelotoxicity, other side effects and effectiveness of L-platin in highly pretreated relapsed , metastatic solid childhood tumors or in children with solid tumors after nefrotoxity problem of previous chemotherapies. Methods: Ten patients (pts) enrolled to study from july 2014 to January 2015, ages between 4 - 15 years (7 boys, 3 girls) with relapsed, metastatic solid tumors ( 3 rhabdo, 2 neuroblastoma; relapsed after high dose therapy followed by ASCT ,3 Osteosarcoma, 1Ewing sarcoma, 1 condrosarcoma). Pts received L-platin (for first 5 pts 125-175 mg /m2,while last 5 patients got 175 mg/m2 and Paclitaxel ( 125-175 mg/m2, before L-platin administration) every other week between 2 to 10 cycles (Median:5, total 52). One patients received L-platin with liposomal doxo while 2 others were received L-platin with Doxo according to their chemo plan. Renal function tests, blood counts, vomiting and other side effects recorded before and after each cycle besides clinical follow-up to asses clinical effectiveness. Results: Creatin levels before treatment were 0.22 - 0.92 mg/ dl (median: 0,47 ) while it was between 0.38 - 0.82 mg/dl ( median: 0.55) after L-platin-Paclitaxel . There was no renal failure or any other important side effects. Only mild, Grade 1-2 myelosupression, vomiting observed. Although, it is early to evaluate effectiveness of the treatment, it was possible to receive stable or slow progressive disease for 2-13 months in that advanced disease patients with better quality of life. Conclusions: According to preliminary results; L-platin is effective and well tolerated by children with relapsed and metastatic cancer with no severe side effects . It may even serve as an option as first line therapy for advanced stage, metastatic childhood solid tumors to prevent any renal or neurological side effects before they observed.
P0992 : Metabolic disturbances after fructose overconsumption are not linked to intestinal permeability in healthy young volunteers
Authors: C. Kienbacher, W. Dolak, S. Traussnigg, P. Steindl-Munda, K. Oettl, V. Stadlbauer, S. Knapp, H. Vogelsang, M. Trauner
Journal: Journal of Hepatology (2015)
The Presence of BCP/PC Variants Reduces the Rate of HBsAg Loss among HBeAg-Positive CHB Patients Treated with Long-Term Tenofovir DF Therapy
Authors: A. Thompson, J. Bayliss, L. Yuen, M. Littlejohn, K. Jackson, D. Wong, A. Gaggar, K. Kitrinos, M. Subramanian, P. Marcellin, E. Gane, H. Chan, S. Bowden, S. Locarnini, P. Revill
Journal: Journal of Hepatology (2016)
Cost-Effectiveness Analysis of Hepatitis B Virus Screening to Prevent Hepatitis B Virus Reactivation in Patients Receiving Rituximab Based Chemotherapy for Hematologic Malignancy
Authors: M. Buti, J. Crespo, R. Esteban, C. Torres, I. Oyagüez, M.Á. Casado
Journal: Journal of Hepatology (2016)
A perspective on single cell behavior during infection
Authors: Roi Avraham, Deborah T. Hung
Journal: Gut Microbes (2016)

The interface between immune cells and intracellular bacterial pathogens produces complex, diverse interactions. During individual encounters, highly adaptable and dynamic host cells and bacteria vary in their responses, thereby contributing to well-documented heterogeneous outcomes of infection. The challenge now is to break down the multidimensionality of these interactions into informative readouts of population physiology and predictors of responses to infection. We recently reported one approach to this challenge that couples single cell RNA-seq analysis with fluorescent markers to characterize infection phenotype.Citation1 We detected bacterial subpopulations that elicit profoundly different host responses to infection in the specific host cells that they infect. Here we describe how heterogeneity might be maintained in populations of host and pathogens and discuss the advantages that heterogeneity confers to bacteria during infection and to host cells for eradicating a pathogen. We propose that single cell studies will allow the unraveling of host-pathogen biology and lead to an understanding of how the sum of individual encounters leads to the infection outcome of a whole organism.
Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer
Authors: Abiy Agiro, Qinli Ma, Anupama Kurup Acheson, Sze-jung Wu, Debra A. Patt, John J. Barron, Jennifer L. Malin, Alan Rosenberg, Richard L. Schilsky, Gary H. Lyman
Journal: Journal of Clinical Oncology (2016)

Purpose To describe outcomes after granulocyte colony-stimulating factor (G-CSF) prophylaxis in patients with breast cancer who received chemotherapy regimens with low-to-intermediate risk of induction of neutropenia-related hospitalization. Patients and Methods We identified 8,745 patients age ≥ 18 years from a medical and pharmacy claims database for 14 commercial US health plans. This retrospective analysis included patients with breast cancer who began first-cycle chemotherapy from 2008 to 2013 using docetaxel and cyclophosphamide (TC); docetaxel, carboplatin, and trastuzumab (TCH); or doxorubicin and cyclophosphamide (conventional-dose AC) regimens. Primary prophylaxis (PP) was defined as G-CSF administration within 5 days of beginning chemotherapy. Outcome was neutropenia, fever, or infection-related hospitalization within 21 days of initiating chemotherapy. Multivariable regressions and number-needed-to-treat analyses were used. Results A total of 4,815 patients received TC (2,849 PP; 1,966 no PP); 2,292 patients received TCH (1,444 PP; 848 no PP); and 1,638 patients received AC (857 PP; 781 no PP) regimen. PP was associated with reduced risk of neutropenia-related hospitalization for TC (2.0% PP; 7.1% no PP; adjusted odds ratio [AOR], 0.29; 95% CI, 0.22 to 0.39) and TCH (1.3% PP; 7.1% no PP; AOR, 0.19; 95% CI, 0.12 to 0.30), but not AC (4.7% PP; 3.8% no PP; AOR, 1.21; 95% CI, 0.75 to 1.93) regimens. For the TC regimen, 20 patients (95% CI, 16 to 26) would have to be treated for 21 days to avoid one neutropenia-related hospitalization; with the TCH regimen, 18 patients (95% CI, 13 to 25) would have to be treated. Conclusion Primary G-CSF prophylaxis was associated with low-to-modest benefit in lowering neutropenia-related hospitalization in patients with breast cancer who received TC and TCH regimens. Further evaluation is needed to better understand which patients benefit most from G-CSF prophylaxis in this setting.